- The
new facility is designed to demonstrate the company’s innovative Ultra
Shear Technology’s ability to create CBD oil nanoemulsions of superior
stability, aesthetics, and bioavailability
- Company
has received orders for nine UST-based BaroShear K45 proprietary systems,
with three more anticipated shortly, for an overall value of $2.4 million
- Global
nanoemulsion market estimated to rise to $14.91 billion by the end of 2025
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the worldwide biotechnology,
biotherapeutics, and other industries, recently announced the opening of their
new Ultra Shear Technology(TM) Demonstration Laboratory, located in the
company’s South Easton, MA facility (http://ibn.fm/veoMI).
The main goal of the UST Demo Lab is to showcase the ability
of the company’s revolutionary UST Platform to process cannabidiol (CBD) oil
into water-soluble nanoemulsions of superior quality. CBD nanoemulsions are
expected to be more stable and offer higher bioavailability than the standard
macro and microemulsions used in the vast majority of CBD products today.
The second objective is to invite potential purchasers of
the company’s BaroShear nanoemulsification system to evaluate how their CBD and
other product formulations work with the company’s revolutionary UST platform.
The company expects to install and invoice the initial 12 BaroShear K45 systems
in the fourth quarter of 2020.
CBD and other cannabinoids are extracted from hemp in an oil
form. As with any oil-based product, it is difficult for the water-based
biology of the human body to access and absorb CBD molecules from relatively
large hemp oil drops. This varying, poor absorption of CBD results in reduced
bioavailability of the CBD molecule in the body. Low or widely varying
absorption levels and bioavailability of CBD have a negative impact on the
effective delivery of many CBD products’ potential benefits.
“We processed samples of CBD oil formulations from several
highly interested companies over the past two months, in an effort to optimize
the service we announced today,” Kenneth F. Micciche, UST Program director,
stated in a news release. “The ability to showcase the UST platform in real
life, and see the final product first-hand, has been shown to be vital to our
marketing efforts. The opening of the UST Demo Lab is a critical accomplishment
in our UST sales and marketing strategy.”
The UST Platform’s efficiency has already brought Pressure
BioSciences several orders for the proprietary UST-based BaroShear K45 Systems.
On January 24, the company announced it had received an order for six BaroShear
K45 systems from Vegas CBD Factory, to be delivered and installed in the fourth
quarter of 2020. This brings the total number of systems on order to nine and,
what’s more, the company expects additional orders shortly. When these are received,
the planned initial build of 12 systems will sell out with approximate total
value of $2.4 million (http://ibn.fm/XpHEF).
In addition to CBD, Pressure BioSciences’ innovative
pressure-based instruments are also used successfully in many different
healthcare areas, such as supporting important research studies in new
treatments for cancer, stroke, heart disease, infectious diseases and
Alzheimer’s. UST therefore has the potential to have a significant impact in
many multi-billion-dollar markets in addition to cannabis, such as cosmetics,
nutraceuticals, pharmaceuticals, and foods and beverages.
The company is also uniquely positioned to leverage an
increasing number of opportunities on the fast-growing nanoemulsion market.
According to Transparency Market Research, the market will see exponential
growth over the next few years, being expected to reach $14.91 billion by the
end of 2025 from $6.78 billion in 2016 (http://ibn.fm/wvCVi).
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
